Rhythm PharmaceuticalsRYTM -0.49%56 Days Inventory is 346.82 as of Mar. 2026, which is 34% above its 10-year median of 259.08. GuruFocus rates RYTM with a GF Score™ of 56/100 and a GF Value™ of $110.90 (Fairly Valued). The stock has 3 warning signs investors should review. Among 638 Biotechnology companies, Rhythm Pharmaceuticals ranks worse than 74.61% on this metric.
The historical rank and industry rank for Rhythm Pharmaceuticals's Days Inventory or its related term are showing as below:
RYTM'
s Days Inventory Range Over the Past 10 Years
Min: 67.64 Med: 259.08 Max: 416.59
Current: 364.03
During the past 11 years, Rhythm Pharmaceuticals's highest Days Inventory was 416.59. The lowest was 67.64. And the median was 259.08.
RYTM's Days Inventory is ranked worse than 74.61% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs RYTM: 364.03
Rhythm Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (475.97) to Mar. 2026 (346.82).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Rhythm Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.26.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Rhythm Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.45.
Rhythm Pharmaceuticals (NAS:RYTM) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Rhythm Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Rhythm Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Rhythm Pharmaceuticals Days Inventory Related Terms
Rhythm Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Rhythm Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RYTM vs MIRM, SYRE, PTGX: Days Inventory Comparison
For the Biotechnology subindustry, Rhythm Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals (RYTM) has a Days Inventory of 346.82 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Rhythm Pharmaceuticals and its competitors. This is 34% above median its historical median of 259.08. Over the past decade, Rhythm Pharmaceuticals' Days Inventory has ranged from 67.64 to 416.59. According to the industry distribution chart, Rhythm Pharmaceuticals ranks #476 out of 638 companies in the Biotechnology industry, placing it in the top 74.6%.
Is Rhythm Pharmaceuticals' Days Inventory too high?
Rhythm Pharmaceuticals' current Days Inventory of 346.82 is 34% above median its 10-year median of 259.08. Over the past 10 years, this metric has ranged from a low of 67.64 to a high of 416.59. The Biotechnology industry median Days Inventory is 183.88. Rhythm Pharmaceuticals' value of 346.82 is 88.6% above this industry median. Based on the distribution chart, Rhythm Pharmaceuticals ranks #476 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Days Inventory compare to MIRM and SYRE?
According to the Biotechnology industry distribution chart, Rhythm Pharmaceuticals ranks #476 out of 638 companies for Days Inventory. This places Rhythm Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 183.88. Rhythm Pharmaceuticals' value of 346.82 is 88.6% above this benchmark. Historically, Rhythm Pharmaceuticals' own Days Inventory has ranged from 67.64 to 416.59 over the past decade. While the company's 10-year median is 259.08 vs. the industry median of 183.88, Rhythm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Pharmaceuticals's current Days Inventory of 346.82 is 88.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Rhythm Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Pharmaceuticals's current Days Inventory is 346.82, which is 34% above median its own 10-year median of 259.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals (RYTM) is currently considered Fairly Valued. The stock's GF Value™ is $110.90, compared to a current price of $110.42 — trading 0.4% below its estimated fair value. The current Days Inventory is 346.82, which is 34% above median its 10-year median of 259.08 and 88.6% above the Biotechnology industry median of 183.88. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Rhythm Pharmaceuticals (RYTM), the current Days Inventory is 346.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhythm Pharmaceuticals (RYTM) Overvalued in 2026?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued.
The current stock price of $110.42 is trading 0.4% below its estimated GF Value™ of $110.90.
GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.
Key valuation signals for RYTM:
Days Inventory: 346.82 (34% above median its 10-year median of 259.08)
GF Value™: $110.90 vs. price of $110.42 (0.4% below fair value)
Industry Position: 88.6% above the Biotechnology median (#476 of 638)
No single metric tells the full story. See the RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score
Get the complete analysis for RYTM
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYTM has been successfully added to your 
